Caffeine and coffee as therapeutics against Alzheimer's disease.

  title={Caffeine and coffee as therapeutics against Alzheimer's disease.},
  author={Gary W. Arendash and Chuanhai Cao},
  journal={Journal of Alzheimer's disease : JAD},
  volume={20 Suppl 1},
  • G. ArendashC. Cao
  • Published 14 April 2010
  • Biology, Psychology
  • Journal of Alzheimer's disease : JAD
Epidemiologic studies have increasingly suggested that caffeine/coffee could be an effective therapeutic against Alzheimer's disease (AD). We have utilized a transgenic mouse model for AD in well-controlled studies to determine if caffeine and/or coffee have beneficial actions to protect against or reverse AD-like cognitive impairment and AD pathology. AD mice given caffeine in their drinking water from young adulthood into older age showed protection against memory impairment and lower brain… 

Figures from this paper

Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease

It is critically important to validate potential prevention strategies such as coffee and caffeine to validate findings from pre-clinical models and improved epidemiological studies that incorporate more standardized methods of data collection and analysis.

The neuroprotective effects of caffeine in neurodegenerative diseases

Caffeine is protective in AD and PD at dosages equivalent to 3‐5 mg/kg, however, further research is needed to investigate the effects of caffeine on PD in women, and caffeine's most salient mechanisms of action relevant to neurodegenerative diseases need to be further explored.

Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging

The observations of adverse caffeine effects in an Alzheimer’s disease model together with previous clinical observations suggest that an exacerbation of BPSD-like symptoms may partly interfere with the beneficial cognitive effects of caffeine.

Risk Reduction of Alzheimer's Disease by Coffee and Caffeine

Beneficial effects of caffeine lead to the phase 2-3 clinical trial of newly developed selective A 2A receptor antagonist for the treatment dementia and Alzheimer’s disease.

Neuroprotective Effect of Caffeine in Alzheimer’s Disease

There is robust evidence based on in vivo and in vitro studies that caffeine has neuroprotective properties in AD animal models, but further studies are needed to identify the mechanistic pathways mediating these effects.

Caffeine blocks cholesterol-enriched diet induced AD-like pathology in rabbits

It is suggested that caffeine exerts its protective effects against the development of sporadic AD-like pathological features, in part, by preventing the entrance of LDL cholesterol into brain parenchyma, the accumulation of LDL-cholesterol in neuronal endolysosomes, and structural and functional changes to endolySosomes.

Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells

Combination of Caff or Coff, before treatment with Mel elicits an additive antiamyloidogenic effects in N2a/APP cells, probably through inhibition of Aβ oligomerization and modulation of the Akt/GSK3β/Tau signaling pathway.

Caffeine and alzheimer's disease

The various individually active metabolites of Caffeine (paraxanthine, theophylline and theobromine) have physiological activity yet their administration alone does not produce similar cognitive benefits, nor alter blood and brain levels of amyloid-beta, indicating the key importance of caffeine itself.



Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain β-amyloid production

Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.

Even with pre-existing and substantial Abeta burden, aged APPsw mice exhibited memory restoration and reversal of AD pathology, suggesting a treatment potential of caffeine in cases of established AD.

Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.

It is reported that acute caffeine administration to both young adult and aged AD transgenic mice rapidly reduces Abeta levels in both brain interstitial fluid and plasma without affecting Abeta elimination, indicating a therapeutic value of caffeine against AD and that plasma Abeta Levels are not an accurate index of brain Abetas levels/deposition or cognitive performance in aged AD mice.

Does caffeine intake protect from Alzheimer's disease?

Caffeine intake was associated with a significantly lower risk for AD, independently of other possible confounding variables, and may have a major impact on the prevention of AD.

Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease

Caffeine blocked high cholesterol diet-induced increases in extravasation of IgG and fibrinogen, increases in leakage of Evan's blue dye, decreases in levels of the tight junction proteins occludin and ZO-1, and increases in astrocytes activation and microglia density where IgGextravasation was present.

Environmental enrichment improves cognition in aged Alzheimer's transgenic mice despite stable &bgr;-amyloid deposition

The results suggest that long-term EE/cognitive stimulation could provide cognitive stabilization or improvement to AD patients through mechanisms independent of A&bgr; deposition and clearance.

Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study.

Caffeine drinkers at midlife had lower risk of dementia and AD later in life compared with those drinking no or only little coffee adjusted for demographic, lifestyle and vascular factors, apolipoprotein E epsilon4 allele and depressive symptoms.

Adenosine A2A receptor blockade prevents memory dysfunction caused by β-amyloid peptides but not by scopolamine or MK-801